|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
|
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Current assets: | |||||||||
| Cash and cash equivalents | |||||||||
| Accounts receivable | |||||||||
| Inventories | |||||||||
| Prepaid expenses | |||||||||
| Other current assets | |||||||||
| Total current assets | |||||||||
| Property and equipment, net | |||||||||
| Operating lease right of use assets | |||||||||
| Nonrelated Party | |||||||||
| Related Party | |||||||||
| Goodwill | |||||||||
| Other intangible assets | |||||||||
| Deferred income taxes | |||||||||
| Other assets | |||||||||
| Total assets | |||||||||
| Liabilities and Equity | |||||||||
| Liabilities | |||||||||
| Current liabilities: | |||||||||
| Current installments of long-term debt | |||||||||
| Accounts payable | |||||||||
| Accrued salaries and benefits | |||||||||
| Other accrued expenses and liabilities | |||||||||
| Total current liabilities | |||||||||
| Long-term debt, less current installments | |||||||||
| Long-term operating lease liability | |||||||||
| Nonrelated Party | |||||||||
| Related Party | |||||||||
| Total long-term operating lease liability | |||||||||
| Self-insured liabilities | |||||||||
| Other long-term liabilities | |||||||||
| Total liabilities | |||||||||
| Redeemable noncontrolling interests | |||||||||
| Common units, no and unlimited units authorized as of December 31, 2024 and December 31, 2023, respectively; no and 484,922,828 units issued and outstanding as of December 31, 2024 and December 31, 2023, respectively | |||||||||
| Equity: | |||||||||
| Preferred stock, par value $0.01 per share; 50,000,000 shares authorized; no shares issued and outstanding | |||||||||
| Common stock, par value $0.01 per share; 750,000,000 shares authorized; 141,910,898 and 142,864,171 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | |||||||||
| Additional paid-in capital | |||||||||
| Accumulated other comprehensive loss | |||||||||
| Retained earnings | |||||||||
| Equity attributable to Ardent Health, Inc. | |||||||||
| Noncontrolling interests | |||||||||
| Total equity | |||||||||
| Total liabilities and equity |
Loading...
